Tebipenem Pivoxil Drug Asset Due Diligence Report 2026

This Tebipenem Pivoxil Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Tebipenem Pivoxil can convert its Small molecule drug profile and PBPs biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tebipenem Pivoxil (query alias: tebipenem pivoxil)
Modality / target	Small molecule drug; PBPs; PBPs inhibitors
Highest global status	Approved
Originator	Meiji Seika Pharma Co., Ltd.
Active developers	Spero Therapeutics, Inc., GSK Plc, Hangzhou Beijia Pharmaceutical Technology Co., Ltd.

The MCP disease footprint includes Complicated urinary tract infection, Pyelonephritis, Otitis Media. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06059846	Phase 3	Completed	1690	Number of Participants With Overall Response at the Test-of-Cure (TOC) Visit in the Microbiological Intent-to-Treat (Micro-ITT) Population
NCT06727136	Phase 1	Completed	39	Part A and B: Maximum Observed Concentration (Cmax) of TBP in Plasma and Blood
NCT05856747	Phase 1	Completed	20	Percentage of Tebipenem (TBP) Samples With Converted (From Whole Blood Measurements) and Measured Plasma Concentrations That Have a Difference not Exceeding ±20% of the Mean of the Concentrations

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Multinational Study to Assess the Efficacy and Safety of Orally Administered Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenously Administered Imipenem-cilastatin in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Phase 3; n=1690; evaluation: not stated. Reported fields: ADR = 291 Participants ; -; ADR = 261 Participants

GSK and Spero's oral antibiotic succeeds in pivotal UTI study

Phase 3; n=1690; evaluation: Non-inferior. Reported fields: Composite endpoint(clinical cure plus microbiological eradication) = tebipenem HBr achieved non-inferiority compared to IV imipenem cilastatin ; Composite endpoint(clinical cure plus microbiological eradication) = tebipenem HBr achieved non-inferiority compared to IV imipenem cilastatin

A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Phase 3; n=1372; evaluation: not stated. Reported fields: Overall Response (Combined Clinical Cure and Microbiological Eradication) at Test-of-Cure (TOC) in Micro Intent-to-Treat Population = 258 Participants ; Overall Response (Combined Clinical Cure and Microbiological Eradication) at Test-of-Cure (TOC) in Micro Intent-to-Treat Population: Risk Difference = -3.3(95% CI, -9.7 to 3.2); Overall Response (Combined Clinical Cure and Microbiological Eradication) at Test-of-Cure (TOC) in Micro Intent-to-Treat Population: Risk Difference = -3.3(95% CI, -9.7 to 3.2)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tebipenem Pivoxil addresses Complicated urinary tract infection, Pyelonephritis, Otitis Media. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-09-21	GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr, a late-stage antibiotic that may treat complicated urinary tract infections	Approved	US$66.0M upfront; US$600.0M stated total
2017-10-10	Spero Therapeutics Licenses Exclusive Rights from Meiji Seika Pharma to SPR994, a Novel Oral Carbapenem Being Studied for Use in Adults	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Refining method of tebipenem pivoxil”. The milestone feed surfaced a patent-application signal described as “High dosage tebipenem pivoxil tablet formulation”. The milestone feed surfaced a patent-application signal described as “Preparation method of tebipenem pivoxil pivoxil fine particles”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO